Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
508
-
Total 13F shares, excl. options
-
92M
-
Shares change
-
+220K
-
Total reported value, excl. options
-
$10.4B
-
Value change
-
+$38.9M
-
Put/Call ratio
-
0.82
-
Number of buys
-
236
-
Number of sells
-
-226
-
Price
-
$112.50
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q3 2023
561 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q3 2023.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 508 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 92M shares
of 99.6M outstanding shares and own 92.37% of the company stock.
Largest 10 shareholders include BlackRock Inc. (13.4M shares), VANGUARD GROUP INC (9.56M shares), STATE STREET CORP (3.84M shares), Bellevue Group AG (2.58M shares), Point72 Asset Management, L.P. (2.58M shares), MORGAN STANLEY (1.92M shares), JPMORGAN CHASE & CO (1.81M shares), JANUS HENDERSON GROUP PLC (1.72M shares), RENAISSANCE TECHNOLOGIES LLC (1.59M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.55M shares).
This table shows the top 508 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.